JP2007504235A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504235A5
JP2007504235A5 JP2006525396A JP2006525396A JP2007504235A5 JP 2007504235 A5 JP2007504235 A5 JP 2007504235A5 JP 2006525396 A JP2006525396 A JP 2006525396A JP 2006525396 A JP2006525396 A JP 2006525396A JP 2007504235 A5 JP2007504235 A5 JP 2007504235A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
heteroarylalkyl
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006525396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504235A (ja
JP4842817B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/028308 external-priority patent/WO2005023815A2/en
Publication of JP2007504235A publication Critical patent/JP2007504235A/ja
Publication of JP2007504235A5 publication Critical patent/JP2007504235A5/ja
Application granted granted Critical
Publication of JP4842817B2 publication Critical patent/JP4842817B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006525396A 2003-09-03 2004-08-31 神経保護二環式化合物およびその使用方法 Expired - Lifetime JP4842817B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49995603P 2003-09-03 2003-09-03
US60/499,956 2003-09-03
PCT/US2004/028308 WO2005023815A2 (en) 2003-09-03 2004-08-31 Neuroprotective bicyclic compounds and methods for their use

Publications (3)

Publication Number Publication Date
JP2007504235A JP2007504235A (ja) 2007-03-01
JP2007504235A5 true JP2007504235A5 (cg-RX-API-DMAC10.html) 2007-10-04
JP4842817B2 JP4842817B2 (ja) 2011-12-21

Family

ID=34272894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525396A Expired - Lifetime JP4842817B2 (ja) 2003-09-03 2004-08-31 神経保護二環式化合物およびその使用方法

Country Status (9)

Country Link
US (2) US8067425B2 (cg-RX-API-DMAC10.html)
EP (1) EP1664050B1 (cg-RX-API-DMAC10.html)
JP (1) JP4842817B2 (cg-RX-API-DMAC10.html)
DK (1) DK1664050T3 (cg-RX-API-DMAC10.html)
ES (1) ES2564803T3 (cg-RX-API-DMAC10.html)
HU (1) HUE028528T2 (cg-RX-API-DMAC10.html)
PL (1) PL1664050T3 (cg-RX-API-DMAC10.html)
SI (1) SI1664050T1 (cg-RX-API-DMAC10.html)
WO (1) WO2005023815A2 (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101632669B (zh) 2000-08-04 2011-05-18 Dmi生物科学公司 二酮基哌嗪和包含它们的组合物的使用方法
EP1648873A4 (en) * 2003-03-20 2008-06-25 Neuren Pharmaceuticals Ltd NEUROPROTECTIVE MACROCYLIC COMPOUNDS AND METHODS OF THEIR APPLICATION
EP2517722B1 (en) 2003-05-15 2016-03-02 Ampio Pharmaceuticals, Inc. Synthesis of diketopiperazines
US8519127B2 (en) * 2003-09-03 2013-08-27 Mike John Bickerdike Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
WO2008063311A2 (en) * 2006-10-11 2008-05-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
US8791117B2 (en) * 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
US8217047B2 (en) 2008-05-27 2012-07-10 Dmi Acquisition Corp. Therapeutic methods and compounds
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
WO2012033792A2 (en) 2010-09-07 2012-03-15 Dmi Acquisition Corp. Treatment of diseases
PH12014500686A1 (en) 2011-10-10 2020-12-18 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
PH12014500685B1 (en) 2011-10-10 2018-10-03 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
CA2846394A1 (en) 2011-10-28 2013-05-02 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
CA2900335C (en) * 2012-10-22 2021-10-26 City Of Hope Synthetic analogs of epipolythiodioxopiperazines and uses thereof
SG11201506267XA (en) 2013-03-15 2015-09-29 Ampio Pharmaceuticals Inc Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
WO2015013397A2 (en) * 2013-07-25 2015-01-29 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
KR102514031B1 (ko) * 2016-05-26 2023-03-27 가부시키가이샤 아미노 압 수면 개선제
US10822353B2 (en) 2016-09-15 2020-11-03 City Of Hope Dithio ETP derivatives
EP4663182A2 (en) 2018-03-16 2025-12-17 Scent Science International Inc. Prophylactic or therapeutic agent for hypoxic injury, ischaemia-reperfusion injury and inflammation, cell protection agent for transplantation, and bio-preservation agent
US11090303B2 (en) 2018-05-15 2021-08-17 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders
CN115243688A (zh) 2019-10-22 2022-10-25 诺仁制药有限公司 双环化合物和它们在治疗pitt hopkins综合征中的使用方法
JP2024507778A (ja) * 2021-02-12 2024-02-21 ニューレン ファーマシューティカルズ リミテッド プラダー・ウィリ症候群の治療
WO2025088052A1 (en) * 2023-10-26 2025-05-01 Rousselot Bv Cyclic analogue of glycine-proline for use in the prevention and/or treatment of medical implant-related fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH469006A (de) * 1965-07-07 1969-02-28 Sandoz Ag Verfahren zur Herstellung neuer synthetischer Alkaloide
EP0626174A3 (en) * 1993-04-21 1996-01-03 Takeda Chemical Industries Ltd Method and composition for the prophylaxis and / or treatment of underactive organs.
US7202279B1 (en) * 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
WO2003039487A2 (en) * 2001-11-09 2003-05-15 Neuronz Limited Cyclo(prolyl-glycine) and methods of use to treat neural disorders
AU2002363800A1 (en) 2001-11-13 2003-05-26 Loi Tran Therapeutic agent composition and method of use
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
EP1648873A4 (en) * 2003-03-20 2008-06-25 Neuren Pharmaceuticals Ltd NEUROPROTECTIVE MACROCYLIC COMPOUNDS AND METHODS OF THEIR APPLICATION

Similar Documents

Publication Publication Date Title
JP2007504235A5 (cg-RX-API-DMAC10.html)
JP2020169171A5 (cg-RX-API-DMAC10.html)
JP2019537599A5 (cg-RX-API-DMAC10.html)
JP2015532295A5 (cg-RX-API-DMAC10.html)
JP2005523922A5 (cg-RX-API-DMAC10.html)
JP2017537940A5 (cg-RX-API-DMAC10.html)
JP2010510237A5 (cg-RX-API-DMAC10.html)
JP2007520440A5 (cg-RX-API-DMAC10.html)
JP2009535307A5 (cg-RX-API-DMAC10.html)
JP2020532547A5 (cg-RX-API-DMAC10.html)
JP2020512337A5 (cg-RX-API-DMAC10.html)
JP2016518437A5 (cg-RX-API-DMAC10.html)
JP2010526146A5 (cg-RX-API-DMAC10.html)
JP2008505157A5 (cg-RX-API-DMAC10.html)
JP2004516314A5 (cg-RX-API-DMAC10.html)
JP2015505296A5 (cg-RX-API-DMAC10.html)
JP2005530811A5 (cg-RX-API-DMAC10.html)
JP2007520452A5 (cg-RX-API-DMAC10.html)
JP2020128426A5 (cg-RX-API-DMAC10.html)
JP2020505354A5 (cg-RX-API-DMAC10.html)
JP2019520344A5 (cg-RX-API-DMAC10.html)
JP2019519593A5 (cg-RX-API-DMAC10.html)
JP2020511536A5 (cg-RX-API-DMAC10.html)
JP2007515467A5 (cg-RX-API-DMAC10.html)
JP2005514456A5 (cg-RX-API-DMAC10.html)